Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

IL-7/IL-7R gene variants impact circulating IL-7/IL-7R homeostasis and ART-associated immune recovery status.

Ceausu A, Rodríguez-Gallego E, Peraire J, López-Dupla M, Domingo P, Viladés C, Vidal-Gonzalez J, Peraire M, Perpiñán C, Pacheco YM, Veloso S, Alba V, Vargas M, Castellano AJ, Ruiz-Mateos E, Mallolas J, Vidal F, Rull A.

Sci Rep. 2019 Oct 31;9(1):15722. doi: 10.1038/s41598-019-52025-8.

2.

Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients?

Milanés-Guisado Y, Gutiérrez-Valencia A, Muñoz-Pichardo JM, Rivero A, Trujillo-Rodriguez M, Ruiz-Mateos E, Espinosa N, Roca-Oporto C, Viciana P, López-Cortés LF.

J Antimicrob Chemother. 2019 Oct 16. pii: dkz421. doi: 10.1093/jac/dkz421. [Epub ahead of print]

PMID:
31617904
3.

Hepatitis C virus and cumulative infections are associated with atherogenic cardiovascular events in HIV-infected subjects.

Genebat M, Tarancón-Díez L, Pulido I, Álvarez-Ríos AI, Muñoz-Fernández MÁ, Ruiz-Mateos E, Leal M.

Antiviral Res. 2019 Sep;169:104527. doi: 10.1016/j.antiviral.2019.05.016. Epub 2019 May 31.

PMID:
31158414
4.

Immunometabolism is a key factor for the persistent spontaneous elite control of HIV-1 infection.

Tarancon-Diez L, Rodríguez-Gallego E, Rull A, Peraire J, Viladés C, Portilla I, Jimenez-Leon MR, Alba V, Herrero P, Leal M, Ruiz-Mateos E, Vidal F; ECRIS integrated in the Spanish AIDS Research Network.

EBioMedicine. 2019 Apr;42:86-96. doi: 10.1016/j.ebiom.2019.03.004. Epub 2019 Mar 14.

5.

High CD8 T cell percentage and HCV replication control are common features in HIV-1 controllers and HTLV-2-co-infected patients with a history of injection drug use.

Ruiz-Mateos E, Ruiz-León MJ, Tarancón-Díez L, Gutiérrez C, Dronda F, Domínguez-Molina B, Pérez-Elías MJ, Moreno A, Leal M, Moreno S, Vallejo A.

Virus Res. 2019 Apr 15;264:40-44. doi: 10.1016/j.virusres.2019.02.007. Epub 2019 Feb 15.

PMID:
30776394
6.

Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance-Supercontrollers.

Dominguez-Molina B, Ferrando-Martinez S, Tarancon-Diez L, Hernandez-Quero J, Genebat M, Vidal F, Muñoz-Fernandez MA, Leal M, Koup R, Ruiz-Mateos E.

Front Immunol. 2018 Dec 10;9:2897. doi: 10.3389/fimmu.2018.02897. eCollection 2018.

7.

Proteomic Profile Associated With Loss of Spontaneous Human Immunodeficiency Virus Type 1 Elite Control.

Rodríguez-Gallego E, Tarancón-Diez L, García F, Del Romero J, Benito JM, Alba V, Herrero P, Rull A, Dominguez-Molina B, Martinez-Madrid O, Martin-Pena L, Pulido F, León A, Rodríguez C, Rallón N, Peraire J, Viladés C, Leal M, Vidal F, Ruiz-Mateos E; HIV-1 Elite Controllers Study Group (ECRIS), Spanish AIDS Research Network.

J Infect Dis. 2019 Feb 23;219(6):867-876. doi: 10.1093/infdis/jiy599.

PMID:
30312441
8.

Toll-Like Receptor 7 (TLR-7) and TLR-9 Agonists Improve Hepatitis C Virus Replication and Infectivity Inhibition by Plasmacytoid Dendritic Cells.

Dominguez-Molina B, Machmach K, Perales C, Tarancon-Diez L, Gallego I, Sheldon JL, Leal M, Domingo E, Ruiz-Mateos E.

J Virol. 2018 Nov 12;92(23). pii: e01219-18. doi: 10.1128/JVI.01219-18. Print 2018 Dec 1.

9.

Improved CD4 T cell profile in HIV-infected subjects on maraviroc-containing therapy is associated with better responsiveness to HBV vaccination.

Herrero-Fernández I, Rosado-Sánchez I, Genebat M, Tarancón-Díez L, Rodríguez-Méndez MM, Pozo-Balado MM, Lozano C, Ruiz-Mateos E, Leal M, Pacheco YM.

J Transl Med. 2018 Aug 29;16(1):238. doi: 10.1186/s12967-018-1617-1.

10.

Altered Expression of CD300a Inhibitory Receptor on CD4+ T Cells From Human Immunodeficiency Virus-1-Infected Patients: Association With Disease Progression Markers.

Vitallé J, Terrén I, Gamboa-Urquijo L, Orrantia A, Tarancón-Díez L, Genebat M, Ruiz-Mateos E, Leal M, García-Obregón S, Zenarruzabeitia O, Borrego F.

Front Immunol. 2018 Jul 23;9:1709. doi: 10.3389/fimmu.2018.01709. eCollection 2018.

11.

Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy.

Rodríguez-Gallego E, Gómez J, Domingo P, Ferrando-Martínez S, Peraire J, Viladés C, Veloso S, López-Dupla M, Beltrán-Debón R, Alba V, Vargas M, Castellano AJ, Leal M, Pacheco YM, Ruiz-Mateos E, Gutiérrez F, Vidal F, Rull A; CORIS-NADES events Study Group.

Atherosclerosis. 2018 Jun;273:28-36. doi: 10.1016/j.atherosclerosis.2018.04.008. Epub 2018 Apr 9.

12.

Role of toll-like receptor 4 Asp299Gly polymorphism in the development of cardiovascular diseases in HIV-infected patients.

Tarancon-Diez L, De Pablo-Bernal RS, Jiménez JL, Álvarez-Ríos AI, Genebat M, Rosado-Sánchez I, Muñoz-Fernández MÁ, Ruiz-Mateos E, Leal M.

AIDS. 2018 May 15;32(8):1035-1041. doi: 10.1097/QAD.0000000000001797.

PMID:
29547441
13.

Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers.

Benito JM, Ortiz MC, León A, Sarabia LA, Ligos JM, Montoya M, Garcia M, Ruiz-Mateos E, Palacios R, Cabello A, Restrepo C, Rodriguez C, Del Romero J, Leal M, Muñoz-Fernández MA, Alcamí J, García F, Górgolas M, Rallón N; ECRIS integrated in the Spanish AIDS Research Network.

BMC Med. 2018 Feb 28;16(1):30. doi: 10.1186/s12916-018-1026-6.

14.

Long-term Persistent Elite HIV-controllers: The Right Model of Functional Cure.

Tarancon-Diez L, Dominguez-Molina B, Viciana P, Lopez-Cortes L, Ruiz-Mateos E.

EBioMedicine. 2018 Feb;28:15-16. doi: 10.1016/j.ebiom.2018.01.013. Epub 2018 Jan 13. No abstract available.

15.

Role of APOBEC3H in the Viral Control of HIV Elite Controller Patients.

Benito JM, Hillung J, Restrepo C, Cuevas JM, León A, Ruiz-Mateos E, Palacios-Muñoz R, Górgolas M, Sanjuán R, Rallón N.

Int J Med Sci. 2018 Jan 1;15(2):95-100. doi: 10.7150/ijms.22317. eCollection 2018.

16.

Pegylated Interferon-α-Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy-Treated HIV-1/Hepatitis C Virus-Coinfected Patients.

Hua S, Vigano S, Tse S, Zhengyu O, Harrington S, Negron J, Garcia-Broncano P, Marchetti G, Genebat M, Leal M, Resino S, Ruiz-Mateos E, Lichterfeld M, Yu XG.

Clin Infect Dis. 2018 Jun 1;66(12):1910-1917. doi: 10.1093/cid/cix1111.

17.

Increased CD127+ and decreased CD57+ T cell expression levels in HIV-infected patients on NRTI-sparing regimens.

Gonzalez-Serna A, Ferrando-Martinez S, Tarancon-Diez L, De Pablo-Bernal RS, Dominguez-Molina B, Jiménez JL, Muñoz-Fernández MÁ, Leal M, Ruiz-Mateos E.

J Transl Med. 2017 Dec 20;15(1):259. doi: 10.1186/s12967-017-1367-5.

18.

Association of heterozygous CCR5Δ32 deletion with survival in HIV-infection: A cohort study.

Ruiz-Mateos E, Tarancon-Diez L, Alvarez-Rios AI, Dominguez-Molina B, Genebat M, Pulido I, Abad MA, Muñoz-Fernandez MA, Leal M.

Antiviral Res. 2018 Feb;150:15-19. doi: 10.1016/j.antiviral.2017.12.002. Epub 2017 Dec 6.

PMID:
29221798
19.

Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection.

Pernas M, Tarancón-Diez L, Rodríguez-Gallego E, Gómez J, Prado JG, Casado C, Dominguez-Molina B, Olivares I, Coiras M, León A, Rodriguez C, Benito JM, Rallón N, Plana M, Martinez-Madrid O, Dapena M, Iribarren JA, Del Romero J, García F, Alcamí J, Muñoz-Fernández M, Vidal F, Leal M, Lopez-Galindez C, Ruiz-Mateos E.

J Virol. 2018 Feb 12;92(5). pii: e01805-17. doi: 10.1128/JVI.01805-17. Print 2018 Mar 1.

20.

Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response.

Herrero-Fernández I, Pacheco YM, Genebat M, Rodriguez-Méndez MDM, Lozano MDC, Polaino MJ, Rosado-Sánchez I, Tarancón-Diez L, Muñoz-Fernández MÁ, Ruiz-Mateos E, Leal M.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e02050-17. doi: 10.1128/AAC.02050-17. Print 2018 Jan.

21.

A Lower Baseline CD4/CD8 T-Cell Ratio Is Independently Associated with Immunodiscordant Response to Antiretroviral Therapy in HIV-Infected Subjects.

Rosado-Sánchez I, Herrero-Fernández I, Álvarez-Ríos AI, Genebat M, Abad-Carrillo MA, Ruiz-Mateos E, Pulido F, González-García J, Montero M, Bernal-Morell E, Vidal F, Leal M, Pacheco YM.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00605-17. doi: 10.1128/AAC.00605-17. Print 2017 Aug.

22.

Reply to Kuniholm et al.

Dominguez-Molina B, Tarancon-Diez L, Leal M, Ruiz-Mateos E.

Clin Infect Dis. 2017 Oct 1;65(7):1244-1245. doi: 10.1093/cid/cix482. No abstract available.

PMID:
28541465
23.

Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers.

Chereau F, Madec Y, Sabin C, Obel N, Ruiz-Mateos E, Chrysos G, Fidler S, Lehmann C, Zangerle R, Wittkop L, Reiss P, Hamouda O, Estrada Perez V, Leal M, Mocroft A, Garcia De Olalla P, Ammassari A, D'Arminio Monforte A, Mussini C, Segura F, Castagna A, Cavassini M, Grabar S, Morlat P, De Wit S, Lambotte O, Meyer L; HIV Controllers Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCOORD.

PLoS One. 2017 Apr 5;12(4):e0173893. doi: 10.1371/journal.pone.0173893. eCollection 2017.

24.

CCR5+ CD8 T-cell levels and monocyte activation precede the onset of acute coronary syndrome in HIV-infected patients on antiretroviral therapy.

Tarancon-Diez L, De Pablo-Bernal RS, Álvarez-Rios AI, Rosado-Sánchez I, Dominguez-Molina B, Genebat M, Pacheco YM, Jiménez JL, Muñoz-Fernández MÁ, Ruiz-Mateos E, Leal M.

Thromb Haemost. 2017 Jun 2;117(6):1141-1149. doi: 10.1160/TH16-11-0867. Epub 2017 Mar 9.

PMID:
28276569
25.

Thymic Function Failure Is Associated With Human Immunodeficiency Virus Disease Progression.

Ferrando-Martinez S, De Pablo-Bernal RS, De Luna-Romero M, De Ory SJ, Genebat M, Pacheco YM, Parras FJ, Montero M, Blanco JR, Gutierrez F, Santos J, Vidal F, Koup RA, Muñoz-Fernández MÁ, Leal M, Ruiz-Mateos E.

Clin Infect Dis. 2017 May 1;64(9):1191-1197. doi: 10.1093/cid/cix095.

26.

Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies.

Petrovas C, Ferrando-Martinez S, Gerner MY, Casazza JP, Pegu A, Deleage C, Cooper A, Hataye J, Andrews S, Ambrozak D, Del Río Estrada PM, Boritz E, Paris R, Moysi E, Boswell KL, Ruiz-Mateos E, Vagios I, Leal M, Ablanedo-Terrazas Y, Rivero A, Gonzalez-Hernandez LA, McDermott AB, Moir S, Reyes-Terán G, Docobo F, Pantaleo G, Douek DC, Betts MR, Estes JD, Germain RN, Mascola JR, Koup RA.

Sci Transl Med. 2017 Jan 18;9(373). pii: eaag2285. doi: 10.1126/scitranslmed.aag2285.

27.

Relationship between CCR5(WT/Δ32) heterozygosity and HIV-1 reservoir size in adolescents and young adults with perinatally acquired HIV-1 infection.

Martínez-Bonet M, González-Serna A, Clemente MI, Morón-López S, Díaz L, Navarro M, Puertas MC, Leal M, Ruiz-Mateos E, Martinez-Picado J, Muñoz-Fernández MA.

Clin Microbiol Infect. 2017 May;23(5):318-324. doi: 10.1016/j.cmi.2016.12.020. Epub 2016 Dec 29.

28.

HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers.

Dominguez-Molina B, Tarancon-Diez L, Hua S, Abad-Molina C, Rodriguez-Gallego E, Machmach K, Vidal F, Tural C, Moreno S, Goñi JM, Ramírez de Arellano E, Del Val M, Gonzalez-Escribano MF, Del Romero J, Rodriguez C, Capa L, Viciana P, Alcamí J, Yu XG, Walker BD, Leal M, Lichterfeld M, Ruiz-Mateos E; ECRIS integrated in the Spanish AIDS Research Network.

Clin Infect Dis. 2017 Mar 1;64(5):621-628. Epub 2016 Dec 16.

29.

Thymic Function Impacts the Peripheral CD4/CD8 Ratio of HIV-Infected Subjects.

Rosado-Sánchez I, Herrero-Fernández I, Genebat M, Ruiz-Mateos E, Leal M, Pacheco YM.

Clin Infect Dis. 2017 Jan 15;64(2):152-158. doi: 10.1093/cid/ciw711. Epub 2016 Oct 20.

PMID:
27986677
30.

Immunovirological Efficacy of Once-Daily Maraviroc Plus Ritonavir-Boosted Atazanavir After 48 Weeks in Naive HIV-Infected Patients.

Pulido I, Genebat M, Alvarez-Rios AI, De Pablo-Bernal RS, Rafii-El-Idrissi Benhnia M, Pacheco YM, Ruiz-Mateos E, Leal M.

Viral Immunol. 2016 Oct;29(8):471-477. Epub 2016 Sep 22.

PMID:
27689417
31.

Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure.

Gonzalez-Serna A, Genebat M, De Luna-Romero M, Tarancon-Diez L, Dominguez-Molina B, Pacheco YM, Muñoz-Fernández MA, Leal M, Ruiz-Mateos E.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6398-401. doi: 10.1128/AAC.01326-16. Print 2016 Oct.

32.

Analysis of Non-AIDS-Defining Events in HIV Controllers.

Dominguez-Molina B, Leon A, Rodriguez C, Benito JM, Lopez-Galindez C, Garcia F, Del Romero J, Gutierrez F, Viciana P, Alcami J, Leal M, Ruiz-Mateos E.

Clin Infect Dis. 2016 May 15;62(10):1304-1309. doi: 10.1093/cid/ciw120. Epub 2016 Mar 1.

PMID:
26936669
33.

Rate and predictors of progression in elite and viremic HIV-1 controllers.

Leon A, Perez I, Ruiz-Mateos E, Benito JM, Leal M, Lopez-Galindez C, Rallon N, Alcami J, Lopez-Aldeguer J, Viciana P, Rodriguez C, Grau E, Iribarren J, Gatell JM, Garcia F; EC and Immune Pathogenesis Working group of the Spanish AIDS Research Network.

AIDS. 2016 May 15;30(8):1209-20. doi: 10.1097/QAD.0000000000001050.

PMID:
26854807
34.

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients.

Gonzalez-Serna A, Genebat M, Ruiz-Mateos E, Leal M.

Drug Des Devel Ther. 2016 Jan 18;10:353-4. doi: 10.2147/DDDT.S100639. eCollection 2016. No abstract available.

35.

Maraviroc contributes to the restoration of the homeostasis of regulatory T-cell subsets in antiretroviral-naive HIV-infected subjects.

Pozo-Balado MM, Rosado-Sánchez I, Méndez-Lagares G, Rodríguez-Méndez MM, Ruiz-Mateos E, Benhnia MR, Muñoz-Fernández MA, Leal M, Pacheco YM.

Clin Microbiol Infect. 2016 May;22(5):461.e1-5. doi: 10.1016/j.cmi.2015.12.025. Epub 2016 Jan 22.

36.

Phenotype and Polyfunctional Deregulation Involving Interleukin 6 (IL-6)- and IL-10-Producing Monocytes in HIV-Infected Patients Receiving Combination Antiretroviral Therapy Differ From Those in Healthy Older Individuals.

De Pablo-Bernal RS, Ramos R, Genebat M, Cañizares J, Rafii-El-Idrissi Benhnia M, Muñoz-Fernández MA, Pacheco YM, Galvá MI, Leal M, Ruiz-Mateos E.

J Infect Dis. 2016 Mar 15;213(6):999-1007. doi: 10.1093/infdis/jiv520. Epub 2015 Oct 30.

PMID:
26518043
37.

Monocyte Phenotype and Polyfunctionality Are Associated With Elevated Soluble Inflammatory Markers, Cytomegalovirus Infection, and Functional and Cognitive Decline in Elderly Adults.

de Pablo-Bernal RS, Cañizares J, Rosado I, Galvá MI, Alvarez-Ríos AI, Carrillo-Vico A, Ferrando-Martínez S, Muñoz-Fernández MÁ, Rafii-El-Idrissi Benhnia M, Pacheco YM, Ramos R, Leal M, Ruiz-Mateos E.

J Gerontol A Biol Sci Med Sci. 2016 May;71(5):610-8. doi: 10.1093/gerona/glv121. Epub 2015 Aug 18.

38.

Maraviroc Clinical Test (MCT) as an alternative tool to decide CCR5-antagonists prescription in naïve HIV-infected patients.

Genebat M, de Pablo-Bernal RS, Pulido I, Jiménez-Mejías ME, Martínez O, Pacheco YM, Raffi-El-Idrissi Benhia M, Abad MA, Ruiz-Mateos E, Leal M.

Antiviral Res. 2015 Sep;121:94-6. doi: 10.1016/j.antiviral.2015.06.018. Epub 2015 Jun 26.

PMID:
26122170
39.

IFNL4 ss469415590 polymorphism is associated with unfavourable clinical and immunological status in HIV-infected individuals.

Machmach K, Abad-Molina C, Romero-Sánchez MC, Dominguez-Molina B, Moyano M, Rodriguez MM, Rafii-El-Idrissi Benhnia M, Jimenez-Mejias ME, Vidal F, Muñoz-Fernández MA, Genebat M, Viciana P, González-Escribano MF, Leal M, Ruiz-Mateos E.

Clin Microbiol Infect. 2015 Mar;21(3):289.e1-4. doi: 10.1016/j.cmi.2014.10.012. Epub 2014 Oct 29.

40.

IFNγ⁻TNFα⁻IL2⁻MIP1α⁻CD107a⁺PRF1⁺ CD8 pp65-Specific T-Cell Response Is Independently Associated With Time to Death in Elderly Humans.

Ferrando-Martínez S, Ruiz-Mateos E, Casazza JP, de Pablo-Bernal RS, Dominguez-Molina B, Muñoz-Fernández MÁ, Delgado J, de la Rosa R, Solana R, Koup RA, Leal M.

J Gerontol A Biol Sci Med Sci. 2015 Oct;70(10):1210-8. doi: 10.1093/gerona/glu171. Epub 2014 Sep 18.

41.

Maintenance of virologic efficacy and decrease in levels of β2-microglobulin, soluble CD40L and soluble CD14 after switching previously treated HIV-infected patients to an NRTI-sparing dual therapy.

Romero-Sánchez MC, Alvarez-Ríos AI, Bernal-Morell E, Genebat M, Vera F, Benhnia MR, Bravo-Urbieta J, Galera-Peñaranda C, de Pablo-Bernal RS, Abad-Carrillo MA, Leal M, Ruiz-Mateos E; VIH-GEMUVIH Región de Murcia Study Group.

Antiviral Res. 2014 Nov;111:26-32. doi: 10.1016/j.antiviral.2014.08.011. Epub 2014 Aug 27.

PMID:
25173576
42.

TNF-α levels in HIV-infected patients after long-term suppressive cART persist as high as in elderly, HIV-uninfected subjects.

De Pablo-Bernal RS, Ruiz-Mateos E, Rosado I, Dominguez-Molina B, Alvarez-Ríos AI, Carrillo-Vico A, De La Rosa R, Delgado J, Muñoz-Fernández MA, Leal M, Ferrando-Martínez S.

J Antimicrob Chemother. 2014 Nov;69(11):3041-6. doi: 10.1093/jac/dku263. Epub 2014 Jul 9.

PMID:
25011654
43.

WNT signaling suppression in the senescent human thymus.

Ferrando-Martínez S, Ruiz-Mateos E, Dudakov JA, Velardi E, Grillari J, Kreil DP, Muñoz-Fernandez MÁ, van den Brink MR, Leal M.

J Gerontol A Biol Sci Med Sci. 2015 Mar;70(3):273-81. doi: 10.1093/gerona/glu030. Epub 2014 Mar 22.

44.

Maraviroc reduces the regulatory T-cell frequency in antiretroviral-naive HIV-infected subjects.

Pozo-Balado MM, Martínez-Bonet M, Rosado I, Ruiz-Mateos E, Méndez-Lagares G, Rodríguez-Méndez MM, Vidal F, Muñoz-Fernández MA, Pacheco YM, Leal M.

J Infect Dis. 2014 Sep 15;210(6):890-8. doi: 10.1093/infdis/jiu180. Epub 2014 Mar 20.

PMID:
24652492
45.

Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects.

Genebat M, Vera F, Hernández-Quero J, Domingo P, Guardiola JM, Martínez-Madrid O, Martínez L, de la Llana FG, Sánchez-Villegas J, Alvarez H, Mariño A, Lluch JF, Martínez-Pérez MA, Marín J, Ruiz-Mateos E, Leal M.

Antiviral Res. 2014 Apr;104:59-61. doi: 10.1016/j.antiviral.2014.01.019. Epub 2014 Jan 31.

PMID:
24491797
46.

Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism.

Gibson RM, Meyer AM, Winner D, Archer J, Feyertag F, Ruiz-Mateos E, Leal M, Robertson DL, Schmotzer CL, Quiñones-Mateu ME.

Antimicrob Agents Chemother. 2014;58(4):2167-85. doi: 10.1128/AAC.02710-13. Epub 2014 Jan 27.

47.

Hepatitis C therapy with interferon-α and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients.

Sun H, Buzon MJ, Shaw A, Berg RK, Yu XG, Ferrando-Martinez S, Leal M, Ruiz-Mateos E, Lichterfeld M.

J Infect Dis. 2014 May 1;209(9):1315-20. doi: 10.1093/infdis/jit628. Epub 2013 Nov 25.

48.

Prevalence of HIV-1 dual infection in long-term nonprogressor-elite controllers.

Pernas M, Casado C, Sandonis V, Arcones C, Rodríguez C, Ruiz-Mateos E, Ramírez de Arellano E, Rallón N, Del Val M, Grau E, López-Vazquez M, Leal M, Del Romero J, López Galíndez C.

J Acquir Immune Defic Syndr. 2013 Nov 1;64(3):225-31. doi: 10.1097/QAI.0b013e31829bdc85.

PMID:
23714744
49.

Long-term suppressive combined antiretroviral treatment does not normalize the serum level of soluble CD14.

Méndez-Lagares G, Romero-Sánchez MC, Ruiz-Mateos E, Genebat M, Ferrando-Martínez S, Muñoz-Fernández MÁ, Pacheco YM, Leal M.

J Infect Dis. 2013 Apr 15;207(8):1221-5. doi: 10.1093/infdis/jit025. Epub 2013 Jan 15.

PMID:
23322858
50.

IL28B single-nucleotide polymorphism rs12979860 is associated with spontaneous HIV control in white subjects.

Machmach K, Abad-Molina C, Romero-Sánchez MC, Abad MA, Ferrando-Martínez S, Genebat M, Pulido I, Viciana P, González-Escribano MF, Leal M, Ruiz-Mateos E; HIV Controllers Consortium of the AIDS Spanish Network.

J Infect Dis. 2013 Feb 15;207(4):651-5. doi: 10.1093/infdis/jis717. Epub 2012 Dec 7.

PMID:
23225905

Supplemental Content

Loading ...
Support Center